Powerful NeOnc Brain Cancer Pipeline Advances
NeOnc Technologies Holdings (NASDAQ: NTHI) is set to meet with the FDA on November 17, 2026, to discuss its experimental brain cancer drug NEO212. This End-of-Phase 1 meeting could pave the way for Phase 2 development and a potential accelerated approval pathway. Early Phase 1 data shows promising tumor reduction and disease control in some patient…